Gasdermin C Protein Level: Could a Potential Biomarker For The Prostate Cancer?

Kurt H.

37th World Congress of Internal Medicine, Praha, Çek Cumhuriyeti, 30 Ekim - 02 Kasım 2024, ss.20

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Praha
  • Basıldığı Ülke: Çek Cumhuriyeti
  • Sayfa Sayıları: ss.20
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Gasdermin C Protein Level: Could a Potential Biomarker For The Prostate Cancer?

Ylli KRASNIQI1, Emine YAGCI2, Ata OZEN3, Cansu OZBAYER2, Hulyam KURT1

1Eskisehir Osmangazi University Medical Faculty Department of Medical Biology, Eskisehir, Turkey. 2Kutahya Saglik Bilimleri University Medical Faculty Department of Medical Biology, Kutahya, Turkey. 3Eskisehir Osmangazi University Medical Faculty Department of Urology, Eskisehir, Turkey. 4Eskişehir Osmangazi University Medical Faculty Department of Medical Biology Üniversitesi, Eskişehir, Turkey

Abstract

Objectives: Prostate cancer is one of the biggest and most important health problems for men. The incidence of prostate cancer is increasing day by day in all countries of the world. Age, race, and family history are the most well-known factors affecting the development of prostate cancer. Numerous studies conducted in recent years have emphasized the importance of pyroptosis on cancer. Pyroptosis is an inflammatory cell death that affects the development and progression of prostate cancer. The aim of our study was to determine the relationship between Gasdermine C protein level and prostate cancer.

Methods: Subjects were divided into two groups: healthy control group (n=120) and prostate cancer group (n=100). GSDMC protein level in serum was measured by ELISA method.

Our study was conducted with the decision numbered 2022-194/40 of the ESOGU Ethics Committee. In the study, blood samples were taken from both groups and the Elisa Kit was used to determine the GSDMC protein level in serum.

Findings: In our study, a statistically significant difference was found between the prostate cancer group and the control group in terms of serum GSDMC protein level (p=0.013).

Conclusions: It is noteworthy that our study is the first to establish a link between GSDMC protein level and prostate cancer and will contribute to the treatment and diagnosis of prostate cancer. New and comprehensive studies with larger sample sizes and evaluating gene and protein changes together are needed.